Lucid Diagnostics Inc. (LUCD)

$0.80 3.50% $0.03 Healthcare

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

$43.46M

Dr. Lishan Aklog M.D.

New York, NY

Oct 14, 2021

-0.67

$-1.21

1.22

1.34

-254,695.08%

-0.03

0.00

3.61

71.68

1.22

-4,753.88%

-8,921.37%

Similar stocks (13)

Integer Holdings Corporation

ITGR

$129.00 -0.52%
Uptrend

Inari Medical, Inc.

NARI

$45.52 9.21%
Downtrend

OrthoPediatrics Corp.

KIDS

$30.66 2.61%
Uptrend

Orthofix Medical Inc.

OFIX

$16.24 -4.64%
Uptrend

Paragon 28, Inc.

FNA

$7.30 1.67%
Downtrend

IRadimed Corporation

IRMD

$44.89 -2.46%
Neutral

Surmodics, Inc.

SRDX

$38.83 -0.44%
Neutral

ClearPoint Neuro, Inc.

CLPT

$11.89 -3.72%
Uptrend

Pulmonx Corporation

LUNG

$7.31 5.33%
Downtrend

NeuroPace, Inc.

NPCE

$7.20 0.42%
Downtrend

CVRx, Inc.

CVRX

$8.42 -1.17%
Downtrend

Electromed, Inc.

ELMD

$17.25 0.82%
Uptrend

Beyond Air, Inc.

XAIR

$0.41 -5.83%
Downtrend

ETF Exposure (5)

Vanguard Extended Market Index Fund Institutional Shares

VIEIX

0%

$129.08 -1.69%
Neutral

Vanguard Total Stock Market Index Fund

VITSX

0%

$129.67 -1.71%
Neutral

Vanguard Total Stock Market Index Fund

VTI

0%

$266.44 -1.66%
Neutral

Vanguard Total Stock Market Index Fund

VTSAX

0%

$129.65 -1.71%
Neutral

Vanguard Extended Market Index Fund

VXF

0%

$170.15 -1.70%
Neutral